| Name | Synairgen |
|---|---|
| Epic | SNG |
| Isin | GB00B0381Z20 |
| Index | AIM100 AIM350 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 4.57p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £9.26 | Debt ratio | n/a |
| Shares in issue | 201.37 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -100.34 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -8.76 | 52-week high / low | 3.40p / 9.80p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Synairgen |
|---|---|
| Address | Mailpoint 810, Southampton General Hospital, Tremona Road, Southampton, United Kingdom, SO16 6YD |
| Telephone | 44 (0) 23 8051 2800 |
| Website | http://www.synairgen.com |
| Director | Position |
|---|---|
| Mr Richard J Marsden | CEO |
| Dr Felicity Gabbay | Non-Executive Director |
| Mr Simon J B Shaw | Non-Executive Chairman |
| Mr Bruce Campbell | Independent Non-Executive Director |
| Prof. Stephen T Holgate | Independent Non-Executive Director |
| Ms Amanda Radford | Independent Non-Executive Director |
| Mr Phillip David Monk | Chief Scientific Officer |
| Mr Joseph Colliver | CFO & Executive Director |
| Assets £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Reporting date | 31/12/22 | 31/12/21 | 31/12/20 |
| Intangible asssets and goodwill | 0.04 | 0.05 | 0.04 |
| Investments and other non-current assets | n/a | n/a | n/a |
| Total non-current assets | 0.13 | 0.23 | 0.39 |
| Inventory / work in progress | n/a | n/a | 0.04 |
| Trade and other receivables | 3.72 | 10.59 | 9.37 |
| Cash and equivalents | 15.93 | 33.83 | 74.98 |
| Other current assets and asset held for resale | 3.75 | n/a | 3.77 |
| Total of all assets | 23.53 | 44.64 | 88.55 |
| Liabilities £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Short term liabilities | 3.25 | 7.64 | 3.41 |
| Long term liabilities | n/a | n/a | n/a |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 3.25 | 7.64 | 3.41 |
| Net assets £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Net assets | 20.27 | 37 | 85.14 |
| Equity £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Share capital | 2.01 | 2.01 | 2 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | -107.47 | -90.74 | -42.59 |
| Share premium account | 125.25 | 125.25 | 125.25 |
| Total equity | 20.27 | 37 | 85.14 |
| Income £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -20.3 | -57.87 | -17.74 |
| Pre-tax profit | -20.09 | -57.86 | -17.73 |